LCM
ADCT icon

Laurion Capital Management’s ADC Therapeutics ADCT Stock Holding History

Laurion Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-120,881
Closed -$260K – 483
2023
Q2 		$260K Buy
+120,881
New +$272K ﹤0.01% 459
2020
Q4 		– Sell
-55,000
Closed -$1.81M – 611
2020
Q3 		$1.81M Buy
55,000
+41,012
+293% +$1.78M 0.02% 326
2020
Q2 		$655K Buy
+13,988
New +$531K 0.01% 551

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Laurion Capital Management's ADCT Position: Q3 2023 in Review

Laurion Capital Management sold out of ADC Therapeutics (ADCT) in Q3 2023, closing a stake of 120,881 shares — an estimated $260K sold.

Laurion Capital Management first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $1.81M in Q3 2020. 41 funds tracked by Wall St. Rank hold ADCT as of Q3 2023.

  • Laurion Capital Management reported no remaining ADC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Laurion Capital Management sold 120,881 ADC Therapeutics shares in Q3 2023, an estimated $260K.
  • Laurion Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Laurion Capital Management's ADC Therapeutics position peaked at $1.81M in Q3 2020.
  • 41 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.